Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, rituximab (MabThera®) cannot be endorsed for use within NHS Wales in combination with chemotherapy for the treatment of paediatric patients (aged ≥6 months to <18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL). |
||
|
||
Medicine details |
||
| Medicine name | rituximab (MabThera®) | |
| Formulation | 100 mg concentrate for solution for infusion, 500 mg concentrate for solution for infusion | |
| Reference number | 4447 | |
| Indication | In combination with chemotherapy for the treatment of paediatric patients (aged ≥6 months to <18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL) |
|
| Company | Roche Products Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 15/09/2020 | |